Total Payments
$325,831
2024 Payments
$16,808
Companies
49
Transactions
873
Medicare Patients
19,324
Medicare Billing
$4.3M
Payment Breakdown by Category
Consulting$157,780 (48.4%)
Other$99,087 (30.4%)
Travel$49,926 (15.3%)
Food & Beverage$17,292 (5.3%)
Research$1,583 (0.5%)
Education$162.31 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $157,780 | 49 | 48.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $97,162 | 61 | 29.8% |
| Travel and Lodging | $49,926 | 48 | 15.3% |
| Food and Beverage | $17,292 | 700 | 5.3% |
| Honoraria | $1,925 | 1 | 0.6% |
| Unspecified | $1,583 | 9 | 0.5% |
| Education | $162.31 | 5 | 0.0% |
Payments by Type
General
$324,247
864 transactions
Research
$1,583
8 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $75,977 | 62 | $0 (2024) |
| GlaxoSmithKline, LLC. | $35,082 | 44 | $0 (2024) |
| Servier BioInnovation | $32,505 | 4 | $0 (2023) |
| United Rheumatology | $32,204 | 7 | $0 (2021) |
| Eli Lilly and Company | $32,190 | 27 | $0 (2020) |
| Amgen Inc. | $30,031 | 58 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $19,380 | 21 | $0 (2024) |
| EMD Serono, Inc. | $12,130 | 13 | $0 (2019) |
| Celgene Corporation | $11,524 | 10 | $0 (2022) |
| Merck Sharp & Dohme LLC | $7,392 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,808 | 113 | AstraZeneca Pharmaceuticals LP ($8,073) |
| 2023 | $90,784 | 147 | AstraZeneca Pharmaceuticals LP ($41,225) |
| 2022 | $59,905 | 148 | AstraZeneca Pharmaceuticals LP ($15,164) |
| 2021 | $23,552 | 85 | AstraZeneca Pharmaceuticals LP ($11,514) |
| 2020 | $33,814 | 38 | United Rheumatology ($17,500) |
| 2019 | $33,807 | 118 | Eli Lilly and Company ($19,490) |
| 2018 | $28,592 | 100 | Eli Lilly and Company ($11,245) |
| 2017 | $38,569 | 124 | Amgen Inc. ($11,129) |
All Payment Transactions
873 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Consulting Fee | Cash or cash equivalent | $2,148.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/17/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $26.64 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $29.32 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $32.15 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| 11/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $29.12 | General |
| Category: IMMUNOLOGY | ||||||
| 11/16/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $951.50 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/16/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $456.95 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/14/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $30.57 | General |
| Category: Inflammation | ||||||
| 11/11/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $34.08 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $13.83 | General |
| 10/29/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | Lilly USA, LLC | TALTZ (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $29.83 | General |
| Category: Immunology | ||||||
| 10/10/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $920.00 | General |
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $22.18 | General |
| 10/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $31.48 | General |
| Category: IMMUNOLOGY | ||||||
| 10/01/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $29.47 | General |
| Category: IMMUNOLOGY | ||||||
| 09/30/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $32.95 | General |
| Category: Dermatology | ||||||
| 09/24/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $42.10 | General |
| Category: Immunology | ||||||
| 09/18/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $26.68 | General |
| Category: Not Applicable | ||||||
| 09/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL- GROUP, PHASE 2 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS -SLE | Eli Lilly and Company | $614.00 | 1 |
| A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Eli Lilly and Company | $256.80 | 1 |
| Related to multiple studies | EMD Serono, Inc. | $108.16 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $102.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 4,951 | 118,539 | $4.5M | $1.2M |
| 2022 | 41 | 3,472 | 70,684 | $3.5M | $880,605 |
| 2021 | 38 | 6,153 | 113,258 | $5.3M | $1.3M |
| 2020 | 37 | 4,748 | 79,848 | $3.7M | $937,147 |
Total Patients
19,324
Total Services
382,329
Medicare Billing
$4.3M
Procedure Codes
160
All Medicare Procedures & Services
160 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0490 | Injection, belimumab, 10 mg | Office | 2023 | 11 | 5,623 | $843,303 | $217,023 | 25.7% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 12 | 1,380 | $546,480 | $182,279 | 33.4% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 16 | 38,772 | $698,358 | $180,458 | 25.8% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 14 | 39,200 | $705,600 | $153,437 | 21.7% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 29 | 12,632 | $227,376 | $118,754 | 52.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 81 | 6,540 | $313,920 | $117,598 | 37.5% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 12 | 6,081 | $474,240 | $65,004 | 13.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 263 | 419 | $94,275 | $39,821 | 42.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 62 | 289 | $144,500 | $17,273 | 12.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 212 | 768 | $46,320 | $9,654 | 20.8% |
| 82306 | Vitamin d-3 level | Office | 2023 | 245 | 300 | $37,800 | $8,623 | 22.8% |
| J1460 | Injection, gamma globulin, intramuscular, 1 cc | Office | 2023 | 11 | 185 | $18,500 | $6,864 | 37.1% |
| 86160 | Measurement of complement (immune system proteins), antigen, | Office | 2023 | 240 | 589 | $29,450 | $6,843 | 23.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 71 | 82 | $16,400 | $6,106 | 37.2% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 253 | 317 | $22,507 | $5,189 | 23.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 66 | 108 | $18,900 | $5,115 | 27.1% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 266 | 339 | $25,425 | $4,480 | 17.6% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 151 | 484 | $21,810 | $4,411 | 20.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 279 | 367 | $22,020 | $3,773 | 17.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 13 | 29 | $17,400 | $3,588 | 20.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $9,500 | $3,513 | 37.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $12,400 | $3,513 | 28.3% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 195 | 236 | $17,936 | $3,073 | 17.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 284 | 390 | $18,290 | $2,951 | 16.1% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 294 | 400 | $11,600 | $2,001 | 17.2% |
About Dr. Daniel Wallace, M.D
Dr. Daniel Wallace, M.D is a Rheumatology healthcare provider based in Beverly Hills, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1982608717.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Wallace, M.D has received a total of $325,831 in payments from pharmaceutical and medical device companies, with $16,808 received in 2024. These payments were reported across 873 transactions from 49 companies. The most common payment nature is "Consulting Fee" ($157,780).
As a Medicare-enrolled provider, Wallace has provided services to 19,324 Medicare beneficiaries, totaling 382,329 services with total Medicare billing of $4.3M. Data is available for 4 years (2020–2023), covering 160 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Beverly Hills, CA
- Active Since 06/09/2005
- Last Updated 03/22/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1982608717
Products in Payments
- SAPHNELO (Biological) $66,848
- BENLYSTA (Biological) $26,159
- Tavneos (Drug) $13,004
- TAVNEOS (Drug) $5,117
- STELARA (Biological) $4,792
- LUPKYNIS (Drug) $4,586
- CC-220 (Drug) $4,022
- ILARIS (Biological) $3,420
- EVUSHELD (Drug) $3,000
- RINVOQ (Biological) $2,528
- SEROSTIM (Biological) $2,165
- Rituxan (Biological) $1,714
- XELJANZ (Drug) $1,032
- COSENTYX (Biological) $969.16
- COSENTYX (Drug) $854.62
- Ultomiris (Drug) $840.00
- SKYRIZI (Biological) $623.95
- KRYSTEXXA (Biological) $508.60
- TREMFYA (Drug) $415.40
- Humira (Biological) $409.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Beverly Hills
Daphne Scaramangas-Plumley, Md, MD
Rheumatology — Payments: $73,217
Rheumatology $73,217
R Swamy Venuturupalli, M.d, M.D
Rheumatology — Payments: $33,943
Rheumatology $33,943
Dr. David Hallegua, M.d, M.D
Rheumatology — Payments: $28,902
Rheumatology $28,902
Dr. Dahlia Carr, Md, MD
Rheumatology — Payments: $16,793
Rheumatology $16,793
Dr. Renee Rinaldi, Md, MD
Rheumatology — Payments: $8,689
Rheumatology $8,689
Dr. Seymour Levine, Md, MD
Rheumatology — Payments: $4,741
Rheumatology $4,741